Early PHOENIX Data Would Not Have Aided Approval Decision On Amylyx’s Relyvrio – US FDA

 
• By Sue Sutter
Drug Review Profile: Relyvrio
FDA decided not to look at early data from an ongoing Phase III study before approving Relyvrio. • Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews